Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
| dc.contributor.author | Beksaç, Meral | |
| dc.contributor.department | Tıp fakültesi | tr_TR |
| dc.date.accessioned | 2019-06-27T13:40:32Z | |
| dc.date.available | 2019-06-27T13:40:32Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P P12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134. | tr_TR |
| dc.description.index | Wos | |
| dc.description.index | Pubmed | |
| dc.identifier.endpage | 2087 | tr_TR |
| dc.identifier.issue | 12 | tr_TR |
| dc.identifier.other | 10.3324/haematol.2018.194118 | |
| dc.identifier.startpage | 2079 | tr_TR |
| dc.identifier.uri | http://hdl.handle.net/20.500.12575/66848 | |
| dc.identifier.volume | 103 | tr_TR |
| dc.language.iso | en | tr_TR |
| dc.relation.journal | Haematologıca | tr_TR |
| dc.subject | Research Subject Categories::MEDICINE | tr_TR |
| dc.title | Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR | tr_TR |